Diabetes Boom: Which Stocks Will Benefit from the 190-Billion-USD Market!
Reading Time: 3 minutes
The global market for obesity and diabetes therapies is undergoing a structural reassessment: Investment banks like Morgan Stanley and JPMorgan foresee a volume of 190 to 200 billion USD by 2030/2035—driven by GLP-1 medications such as Wegovy, Ozempic, and Zepbound. Supply shortages for injection preparations are largely resolved, insurance coverage and reimbursement are improving, and a new Medicare pilot program is opening a previously closed sales channel for obesity treatments. Winning sector 1: Big Pharma with GLP-1 platforms (Eli Lilly,...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
